124 related articles for article (PubMed ID: 9785889)
1. [A close association of prognosis with effect of interferon in HBV carriers developing acute severe exacervation].
Higuchi D; Sekiyama K; Yoshiba M; Inoue K; Fujita R
Nihon Shokakibyo Gakkai Zasshi; 1998 Sep; 95(9):1001-7. PubMed ID: 9785889
[TBL] [Abstract][Full Text] [Related]
2. Low level hepatitis B viremia detected by polymerase chain reaction accompanies the absence of HBe antigenemia and hepatitis in hepatitis B virus carriers.
Niitsuma H; Ishii M; Miura M; Kobayashi K; Toyota T
Am J Gastroenterol; 1997 Jan; 92(1):119-23. PubMed ID: 8995950
[TBL] [Abstract][Full Text] [Related]
3. Antibody to hepatitis B e positive hepatitis induced by withdrawal of steroid therapy for polymyositis: response to interferon-alpha and cyclosporin A.
Nakanishi K; Ishikawa M; Nakauchi M; Sakurai A; Doi K; Taniguchi Y
Intern Med; 1998 Jun; 37(6):519-22. PubMed ID: 9678685
[TBL] [Abstract][Full Text] [Related]
4. Southern hybridisation analysis of HBV DNA in peripheral blood leucocytes and of different cell types: changes during the natural history and with interferon-alpha therapy in patients with hepatitis B virus infection.
Catterall AP; Murray-Lyon IM; Zuckerman AJ; Harrison TJ
J Med Virol; 1994 Jul; 43(3):269-75. PubMed ID: 7931189
[TBL] [Abstract][Full Text] [Related]
5. Interferon and cyclosporin A in the treatment of fulminant viral hepatitis.
Yoshiba M; Sekiyama K; Inoue K; Fujita R
J Gastroenterol; 1995 Feb; 30(1):67-73. PubMed ID: 7719417
[TBL] [Abstract][Full Text] [Related]
6. [Subclasses of antibodies to hepatitis B core antigen in chronic HBV infections: changes during treatment with interferons and predictors of response].
Cheng GM; Karayiannis P; Thomas HC
Zhonghua Nei Ke Za Zhi; 1990 Mar; 29(3):141-3, 188-9. PubMed ID: 1698593
[TBL] [Abstract][Full Text] [Related]
7. The two different states of hepatitis B virus DNA in asymptomatic carriers: HBe-antigen-positive versus anti-HBe-positive asymptomatic carriers.
Fujiwara K; Yokosuka O; Ehata T; Chuang WL; Imazeki F; Saisho H; Omata M
Dig Dis Sci; 1998 Feb; 43(2):368-76. PubMed ID: 9512133
[TBL] [Abstract][Full Text] [Related]
8. Human lymphoblastoid interferon therapy in chronic hepatitis B virus carriers.
Alexander GJ
Chemioterapia; 1988 Dec; 7 Suppl 3():9-11. PubMed ID: 3248319
[TBL] [Abstract][Full Text] [Related]
9. Outcome of liver disease and response to interferon treatment are not influenced by hepatitis B virus core gene variability in children with chronic type B hepatitis.
Schepis F; Verucchi G; Pollicino T; Attard L; Brancatelli S; Longo G; Raimondo G
J Hepatol; 1997 Apr; 26(4):765-70. PubMed ID: 9126787
[TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular virological differences between fulminant hepatic failures following acute and chronic infection with hepatitis B virus.
Inoue K; Yoshiba M; Sekiyama K; Okamoto H; Mayumi M
J Med Virol; 1998 May; 55(1):35-41. PubMed ID: 9580884
[TBL] [Abstract][Full Text] [Related]
11. Prospective randomized controlled trial of sequential treatment with corticoids and alpha-interferon versus treatment with interferon alone in patients with chronic active hepatitis B.
Niederau C; Heintges T; Niederau M; Stremmel W; Strohmeyer G
Eur J Med; 1992 Nov; 1(7):396-402. PubMed ID: 1341478
[TBL] [Abstract][Full Text] [Related]
12. Treatment of the chronic hepatitis B virus carrier state.
Lever AM
J Infect; 1988 May; 16(3):221-9. PubMed ID: 2456355
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of renal transplantation in hepatitis B surface antigen-positive patients in cyclosporin era.
Yagisawa T; Toma H; Tanabe K; Ishikawa N; Tokumoto N; Iguchi Y; Goya N; Nakazawa H; Takahashi K; Ota K
Am J Nephrol; 1997; 17(5):440-4. PubMed ID: 9382163
[TBL] [Abstract][Full Text] [Related]
14. Influence of human immunodeficiency virus infection on hepatitis delta virus superinfection in chronic HBsAg carriers.
Pol S; Wesenfelder L; Dubois F; Roingeard P; Carnot F; Driss F; Brechot C; Goudeau A; Berthelot P
J Viral Hepat; 1994; 1(2):131-7. PubMed ID: 8790568
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment.
Yoshiba M; Sekiyama K; Sugata F; Okamoto H; Yamamoto K; Yotsumoto S
Dig Dis Sci; 1992 Aug; 37(8):1253-9. PubMed ID: 1499451
[TBL] [Abstract][Full Text] [Related]
16. Dangers of immunosuppressive therapy in hepatitis B virus carriers.
Lueg E; Heathcote J
CMAJ; 1992 Oct; 147(8):1155-8. PubMed ID: 1393929
[TBL] [Abstract][Full Text] [Related]
17. Occult hepatitis B infection in Portuguese patients with chronic hepatitis C liver disease: prevalence and clinical significance.
Cardoso C; Alves AL; Augusto F; Freire R; Quintana C; Gonçalves M; Oliveira AP
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):142-6. PubMed ID: 23044809
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha 2b treatment in hepatitis B carriers. Effect on hepatitis B virus DNA levels in children infected with different genotypes.
Sangfelt P; Norder H; Magnius LO; Alaeus A; Carlsson T; Reichard O
Acta Paediatr; 1997 Feb; 86(2):135-7. PubMed ID: 9055880
[TBL] [Abstract][Full Text] [Related]
19. The influence of occult infection with hepatitis B virus on liver histology and response to interferon treatment in chronic hepatitis C patients.
Silva Cd; Gonçales NS; Pereira JS; Escanhoela CA; Pavan MH; Gonçales FL
Braz J Infect Dis; 2004 Dec; 8(6):431-9. PubMed ID: 15880234
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous reactivation of chronic hepatitis B infection leading to fulminant hepatic failure. Report of two cases and review of the literature.
Meyer RA; Duffy MC
J Clin Gastroenterol; 1993 Oct; 17(3):231-4. PubMed ID: 8228085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
